Amgen to pay $71 million to settle claims of off-label drug uses
Biotechnology company Amgen Inc. has agreed to pay $71 million to 48 states and the District of Columbia to settle claims that it improperly promoted its top-selling drugs, Aranesp and Enbrel, for uses not approved by the Food and Drug Administration.
California will receive $4.6 million from the settlement, Attorney General Kamala Harris announced Tuesday.
Harris and the other attorneys general alleged that Amgen (Nasdaq: AMGN) violated state consumer protection laws by promoting Aranesp for dosing…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Source Type: news
More News: Aranesp | Biotechnology | Enbrel | Food and Drug Administration (FDA) | Health | Health Management | Legislation | Pharmaceuticals